Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment

Journal of Hypertension

Volumn 22, Issue 12, 2004, Pages 2321-2328

  Liljedahl, Ulrika ^a   Kahan, Thomas ^b   Malmqvist, Karin ^b   Melhus, Håkan ^a   Syvänen, Ann Christine ^a   Lind, Lars ^a,c   Kurland, Lisa ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Genotyping; Hypertension; Left ventricular hypertrophy; Microarrays; Minisequencing; Pharmacogenetics; Single nucleotide polymorphism (SNP)

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; ATENOLOL; IRBESARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 10244257519     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200412000-00014     Document Type: Article

References (47)

1. WHO-ISH Guidelines Subcommittee. 1999 World Health Organization- International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-183.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
4. Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994; 272:33-36.
5. Schillaci G, Verdecchia P, Reboldi G, Pede S, Porcellati C. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
6. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
7. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
8. de Simone G, Devereux RB, Roman MJ, Schlussel Y, Alderman MH, Laragh JH. Echocardiographic left ventricular mass and electrolyte intake predict arterial hypertension. Ann Intern Med 1991; 114:202-209.
9. Devereux RB, de Simone G, Koren MJ, Roman MJ, Laragh JH. Left ventricular mass as a predictor of development of hypertension. Am J Hypertens 1991; 4:603S-607S.
10. van Hooft IM, Grobbee DE, Waal-Manning HJ, Hofman A. Hemodynamic characteristics of the early phase of primary hypertension. The Dutch Hypertension and Offspring Study. Circulation 1993; 87:1100-1106.
11. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90:179-185.
12. Bielen E, Fagard R, Amery A. The inheritance of left ventricular structure and function assessed by imaging and Doppler echocardiography. Am Heart J 1991; 121:1743-1749.
13. Verhaaren HA, Schieken RM, Mosteller M, Hewitt JK, Eaves LJ, Nance WE. Bivariate genetic analysis of left ventricular mass and weight in pubertal twins (the Medical College of Virginia twin study). Am J Cardiol 1991; 68:661-668.
14. Post WS, Larson MG, Myers RH, Galderisi M, Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 1997; 30:1025-1028.
15. Turner ST, Kardia SL. Relationship between renal plasma flow response to angiotensin II and blood pressure in a population-based sample. J Hypertens 1997; 15:495-502.
16. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Öhman P, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish lrbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20:657-663.
17. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogeentic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13:7-17.
18. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17:8-13.
19. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
20. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
21. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E, et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol 1986; 57:1388-1393.
22. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
23. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM. Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 1997; 30:1331-1337.
24. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R, Fagard R, et al. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 1999; 17:9-17.
25. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjaerg-Hansen A, et al. Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study. Hypertension 2001; 37:875-881.
26. Sethi AA, Nordestgaard BG, Gronholdt ML, Steffensen R, Jensen G, Tybjaerg-Hansen A. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 2003; 41:1202-1211.
27. Sato N, Katsuya T, Rakugi H, Takami S, Nakata Y, Miki T, et al. Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hypertension 1997; 30:321-325.
28. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99:1786-1797.
29. Ishigami T, Tamura K, Fujita T, Kobayashi I, Hibi K, Kihara M, et al. Angiotensinogen gene polymorphism near transcription start site and blood pressure: role of a T-to-C transition at intron I. Hypertension 1999; 34:430-434.
30. Iwai N, Shimoike H, Ohmichi N, Kinoshita M. Angiotensinogen gene and blood pressure in the Japanese population. Hypertension 1995; 25:688-693.
31. Ishanov A, Okamoto H, Yoneya K, Watanabe M, Nakagawa I, Machida M, et al. Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1997; 133:184-189.
32. Kauma H, Ikaheimo M, Savolainen MJ, Kiema TR, Rantala AO, Lilja M, et al. Variants of renin-angiotensin system genes and echocardiographic left ventricular mass. Eur Heart J 1998; 19:1109-1117.
33. Jeng JR. Left ventricular mass, carotid wall thickness, and angiotensinogen gene polymorphism in patients with hypertension. Am J Hypertens 1999; 12:443-450.
34. Tang W, Devereux RB, Rao DC, Oberman A, Hopkins PN, Kitzman DW, et al. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. Am Heart J 2002; 143:854-860.
35. Innes BA, McLaughlin MG, Kapuscinski MK, Jacob HJ, Harrap SB. Independent genetic susceptibility to cardiac hypertrophy in inherited hypertension. Hypertension 1998; 31:741-746.
36. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z. In search of cardiovascular candidate genes: interactions between phenotypes and genotypes. Hypertension 2002; 39:332-336.
37. Garner C, Lecomte E, Visvikis S, Abergel E, Lathrop M, Soubrier F. Genetic and environmental influences on left ventricular mass. A family study. Hypertension 2000; 36:740-746.
38. Chiodini BD, Barlera S, Franzosi MG, Beceiro VL. Introna M, Tognoni G. APO B gene polymorphisms and coronary artery disease: a meta-analysis. Atherosclerosis 2003; 167:355-366.
39. Sundström J, Lind L, Ärnlöv J, Zethelius B, Andren B, Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 2001; 103:836-841.
40. Series JJ, Gaffney D, Packard CJ, Shepherd J. Frequency of the XbaI, EcoRI, PVuII and MspI polymorphisms of the apolipoprotein B gene in relation to hypercholesterolaemia in the general population. Clin Chim Acta 1993; 215:89-98.
41. Delghandi, Thangarajah R, Nilsen M, Grimsgaard S, Bonaa KH, Tonstad S, et al. DNA polymorphisms of the apolipoprotein B gene (XbaI, EcoRI, and MspI RFLPs) in Norwegians at risk of atherosclerosis and healthy controls. Acta Cardiol 1999; 54:215-225.
42. Bentzen J, Jorgensen T, Fenger M. The effect of six polymorphisms in the Apolipoprotein B gene on parameters of lipid metabolism in a Danish population. Clin Genet 2002; 61:126-134.
43. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem 1992; 267:25621-25624.
44. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108:560-565.
45. Kahan T, Dahlöf C, Hjemdahl P. Prejunctional alpha-adrenoceptor- mediated inhibition of norepinephrine release in blood-perfused skeletal muscle in situ. J Cardiovasc Pharmacol 1987; 9:555-562.
46. Thomas L, Gasser B, Bousquet P, Monassier L. Hemodynamic and cardiac anti-hypertrophic actions of clonidine in Goldblatt one-kidney, one-clip rats. J Cardiovasc Pharmacol 2003; 41:203-209.
47. Giugliano D, Acampora R, Marfella R, La Marca C, Marfella M, Nappo F, et al. Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1998; 11:184-189.